These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 33372192)

  • 21. Cerebrospinal Fluid and Plasma Biomarkers do not Differ in the Presenile and Late-Onset Behavioral Variants of Frontotemporal Dementia.
    Marelli C; Hourregue C; Gutierrez LA; Paquet C; Menjot de Champfleur N; De Verbizier D; Jacob M; Dubois J; Maleska AM; Hirtz C; Navucet S; Bennys K; Dumurgier J; Cognat E; Berr C; Magnin E; Lehmann S; Gabelle A
    J Alzheimers Dis; 2020; 74(3):903-911. PubMed ID: 32083577
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum and cerebrospinal fluid brain damage markers neurofilament light and glial fibrillary acidic protein correlate with tick-borne encephalitis disease severity-a multicentre study on Lithuanian and Swedish patients.
    Veje M; Griška V; Pakalnienė J; Mickienė A; Bremell D; Zetterberg H; Blennow K; Lindquist L; Studahl M
    Eur J Neurol; 2023 Oct; 30(10):3182-3189. PubMed ID: 37431060
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.
    Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT
    Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic depressive symptomatology and CSF amyloid beta and tau levels in mild cognitive impairment.
    Gonzales MM; Insel PS; Nelson C; Tosun D; Schöll M; Mattsson N; Sacuiu S; Bickford D; Weiner MW; Mackin RS;
    Int J Geriatr Psychiatry; 2018 Oct; 33(10):1305-1311. PubMed ID: 29953668
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparisons in the changes of clinical characteristics and cerebrospinal fluid cytokine profiles between varicella-zoster virus meningitis/encephalitis and other central nervous system infections.
    Ma C; Lu Y; Zhang Q; Chen H; Zhang Q; Hu H; Song Z; Chen R; Liu D
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Oct; 47(10):1345-1354. PubMed ID: 36411685
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
    J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Aβ
    Hampel H; Toschi N; Baldacci F; Zetterberg H; Blennow K; Kilimann I; Teipel SJ; Cavedo E; Melo Dos Santos A; Epelbaum S; Lamari F; Genthon R; Dubois B; Floris R; Garaci F; Lista S;
    Alzheimers Dement; 2018 Apr; 14(4):492-501. PubMed ID: 29328927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease.
    Skogseth RE; Bronnick K; Pereira JB; Mollenhauer B; Weintraub D; Fladby T; Aarsland D
    J Parkinsons Dis; 2015; 5(4):783-92. PubMed ID: 26599300
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.
    Stav AL; Aarsland D; Johansen KK; Hessen E; Auning E; Fladby T
    Parkinsonism Relat Disord; 2015 Jul; 21(7):758-64. PubMed ID: 25971633
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Progression from mild to pronounced MCI is not associated with cerebrospinal fluid biomarker deviations.
    Wallin A; Göthlin M; Gustavsson M; Zetterberg H; Eckerström C; Blennow K; Edman A; Lind K; Nordlund A; Rolstad S
    Dement Geriatr Cogn Disord; 2011; 32(3):193-7. PubMed ID: 22057225
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid.
    Forlenza OV; Aprahamian I; Radanovic M; Talib LL; Camargo MZ; Stella F; Machado-Vieira R; Gattaz WF
    Bipolar Disord; 2016 Feb; 18(1):63-70. PubMed ID: 26876913
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CSF Biomarkers Reflecting Protein Pathology and Axonal Degeneration Are Associated with Memory, Attentional, and Executive Functioning in Early-Stage Parkinson's Disease.
    Oosterveld LP; Kuiper TI; Majbour NK; Verberk IMW; van Dijk KD; Twisk JWR; El-Agnaf OM; Teunissen CE; Weinstein HC; Klein M; Berendse HW; van de Berg WDJ
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33198266
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer's Disease Dementia.
    Mazzeo S; Santangelo R; Bernasconi MP; Cecchetti G; Fiorino A; Pinto P; Passerini G; Falautano M; Comi G; Magnani G
    J Alzheimers Dis; 2016 Oct; 54(4):1495-1508. PubMed ID: 27589522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of Cerebrospinal Fluid Neurofilament Light Protein With Risk of Mild Cognitive Impairment Among Individuals Without Cognitive Impairment.
    Kern S; Syrjanen JA; Blennow K; Zetterberg H; Skoog I; Waern M; Hagen CE; van Harten AC; Knopman DS; Jack CR; Petersen RC; Mielke MM
    JAMA Neurol; 2019 Feb; 76(2):187-193. PubMed ID: 30419087
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detection.
    Peterson J; Gisslen M; Zetterberg H; Fuchs D; Shacklett BL; Hagberg L; Yiannoutsos CT; Spudich SS; Price RW
    PLoS One; 2014; 9(12):e116081. PubMed ID: 25541953
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amyloid-β₄₂ is associated with cognitive impairment in healthy elderly and subjective cognitive impairment.
    Rolstad S; Berg AI; Bjerke M; Blennow K; Johansson B; Zetterberg H; Wallin A
    J Alzheimers Dis; 2011; 26(1):135-42. PubMed ID: 21593572
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual-Task Performance and Neurodegeneration: Correlations Between Timed Up-and-Go Dual-Task Test Outcomes and Alzheimer's Disease Cerebrospinal Fluid Biomarkers.
    Åhman HB; Giedraitis V; Cedervall Y; Lennhed B; Berglund L; McKee K; Kilander L; Rosendahl E; Ingelsson M; Åberg AC
    J Alzheimers Dis; 2019; 71(s1):S75-S83. PubMed ID: 31104024
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Revisiting the Cerebrospinal Fluid Biomarker Profile in Idiopathic Normal Pressure Hydrocephalus: The Bologna Pro-Hydro Study.
    Abu-Rumeileh S; Giannini G; Polischi B; Albini-Riccioli L; Milletti D; Oppi F; Stanzani-Maserati M; Capellari S; Mantovani P; Palandri G; Cortelli P; Cevoli S; Parchi P
    J Alzheimers Dis; 2019; 68(2):723-733. PubMed ID: 30883350
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Associations of Multimorbidity with Cerebrospinal Fluid Biomarkers for Neurodegenerative Disorders in Early Parkinson's Disease: A Crosssectional and Longitudinal Study.
    Zhang MZ; Sun Y; Chen YM; Guo F; Gao PY; Tan L; Tan MS
    Curr Alzheimer Res; 2024; 21(3):201-213. PubMed ID: 39041277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.